The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 101–200 of 1,001
Anxiety, stress, and fear response in mice with reduced endocannabinoid levels
Jenniches, I., Ternes, S., Albayram, O., Otte, D. M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A., & Zimmer, A. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.033 · Cited by 169
Plant, Synthetic, and Endogenous Cannabinoids in Medicine
Marzo, V. D., & Petrocellis, L. D. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.011205.135648 · Cited by 169
Self-citationAwareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder
Khan, A. U., Akram, M., Daniyal, M., & Zainab, R. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1486837 · Cited by 142
Nicotine Gateway Effects on Adolescent Substance Use
Ren, M., & Lotfipour, S. (2019) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2019.7.41661 · Cited by 166
Anand, U., Otto, W. R., Sanchez-Herrera, D., Facer, P., Yiangou, Y., Korchev, Y., Birch, R., Benham, C., Bountra, C., Chessell, I. P., et al. (2008) · Pain · doi:10.1016/j.pain.2008.06.007 · Cited by 166
“While the CB1 receptor is expressed in neurons of the CNS [18] and in DRG neurons [11,25], the CB2 receptor has been localised mostly in lymphoid tissues in the periphery [7,19], although recent evidence suggests that CB2 receptors may be present also in rodent brain [21], and we have shown CB2 immunoreactivity in act…”
BackgroundLoss of Cannabinoid Receptor 1 Accelerates Intestinal Tumor Growth
Wang, D., Wang, H., Ning, W., Backlund, M. G., Dey, S. K., & DuBois, R. N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0896 · Cited by 166
“CB1 and CB2 can activate several different cellular pathways depending on the biological context being examined (4, 7).”
Endocannabinoid system acts as a regulator of immune homeostasis in the gut
Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A. T., Basu, S., & Srivastava, P. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612177114 · Cited by 166
“, TRPV1); and (iii) the enzymes such as fatty acid amide hydrolyase (FAAH) that regulate the levels of endocannabinoids in vivo (2).”
Backgroundβ-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling
Anderson, G. R., Aoto, J., Tabuchi, K., Földy, C., Covy, J., Yee, A. X., Wu, D., Lee, S.-J., Chen, L., Malenka, R. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.056 · Cited by 165
Rajesh, M., Pan, H., Mukhopadhyay, P., Bátkai, S., Osei-Hyiaman, D., Haskó, G., Liaudet, L., Gao, B., & Pacher, P. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307180 · Cited by 148
Horváth, B., Mukhopadhyay, P., Kechrid, M., Patel, V., Tanchian, G., Wink, D. A., Gertsch, J., & Pacher, P. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.01.014 · Cited by 164
Genomic and Chemical Diversity in Cannabis
Lynch, R. C., Vergara, D., Tittes, S., White, K., Schwartz, C. J., Gibbs, M. J., Ruthenburg, T. C., deCesare, K., Land, D. P., & Kane, N. C. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265363 · Cited by 163
Suraev, A. S., Marshall, N. S., Vandrey, R., McCartney, D., Benson, M. J., McGregor, I. S., Grunstein, R. R., & Hoyos, C. M. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101339 · Cited by 161
Medications development: Successes and challenges
Vocci, F., & Ling, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.010 · Cited by 160
Food Ingredients as Anti-Obesity Agents: A Review
Trigueros, L., Peña, S., Ugidos, A. V., Sayas‐Barberá, E., Pérez‐Álvarez, J. Á., & Sendra, E. (2013) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2011.574215 · Cited by 160
“The endocannabinoid system plays an important role in the physiological regulation of food intake, energy balance, as well as lipid and glucose metabolism (Di Marzo et al., 2004).”
BackgroundCheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 159
Rimonabant for overweight or obesity
Curioni, C., & André, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006162.pub2 · Cited by 144
Emerging Therapeutic Strategies for Obesity
Foster-Schubert, K. E., & Cummings, D. E. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0041 · Cited by 142
Monteleone, P., Bifulco, M., Maina, G., Tortorella, A. A. V., Gazzerro, P., Proto, M., Filippo, C. D., Monteleone, F., Canestrelli, B., Buonerba, G., et al. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.002 · Cited by 157
Self-citationThe endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
Massa, F., Storr, M., & Lutz, B. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0698-5 · Cited by 157
“Due to the increased interest in the pharmacological targeting of the endocannabinoid system in the context of various human pathologies, the list of synthetic agonists/antagonists will certainly grow in the very near future [13, 45].”
BackgroundTzavara, E. T., Li, D. L., Moutsimilli, L., Bisogno, T., Marzo, V. D., Phebus, L. A., Nomikos, G. G., & Giros, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.019 · Cited by 157
Self-citationGenetics of Antipsychotic Treatment Emergent Weight Gain in Schizophrenia
Müller, D. J., & Kennedy, J. L. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.863 · Cited by 156
“The endocannabinoid system, for example, represents another energy intake regulator that acts through peripheral and central mechanisms [96].”
BackgroundN-acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans
Lucanic, M., Held, J. M., Vantipalli, M. C., Klang, I. M., Graham, J. B., Gibson, B. W., Lithgow, G. J., & Gill, M. S. (2011) · Nature · doi:10.1038/nature10007 · Cited by 141
Carley, D. W., Prasad, B., Reid, K. J., Malkani, R., Attarian, H., Abbott, S. M., Vern, B., Xie, H., Yuan, C., & Zee, P. C. (2018) · Sleep · doi:10.1093/sleep/zsx184 · Cited by 141
Cannabinoids in pancreatic cancer: Correlation with survival and pain
Michalski, C. W., Oti, F. E., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Bátkai, S., Müller, M. W., Giese, N. A., Frieß, H., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23114 · Cited by 151
“Of these, cannabinoid receptor-1 (CB1)(6) is abundantly found in neural tissues, while cannabinoid receptor-2 (CB2)(7) is particularly expressed on cells of the immune system.(5)”
BackgroundAgonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors
Shoemaker, J. L., Ruckle, M. B., Mayeux, P. R., & Prather, P. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089474 · Cited by 151
“Given potentially important roles for CB2 receptors during development of nociceptive and inflammatory states (Di Marzo et al., 2004), understanding ADTR by can-nabinoids acting at CB2 receptors could significantly impact future drug development for these diseases.”
BackgroundUse of cannabidiol (CBD) for the treatment of chronic pain
Urits, I., Gress, K. L., Charipova, K., Habib, K., Lee, D. M., Lee, C. S., Jung, J. W., Kassem, H., Cornett, E. M., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.004 · Cited by 150
Liu, Q.-R., Canseco-Alba, A., Zhang, H.-Y., Tagliaferro, P., Chung, M., Dennis, E., Sanabria, B., Schanz, N., Escosteguy-Neto, J. C., Ishiguro, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17796-y · Cited by 147
Novel bioactive metabolites of dipyrone (metamizol)
Rogosch, T., Sinning, C., Podlewski, A., Watzer, B., Schlosburg, J. E., Lichtman, A. H., Cascio, M. G., Bisogno, T., Marzo, V. D., Nüsing, R. M., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.028 · Cited by 145
Self-citationMallat, A., Teixeira‐Clerc, F., Deveaux, V, Manin, S., & Lotersztajn, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01397.x · Cited by 131
“Clearance of AEA relies on its cellular uptake by a mechanism that may involve a specific AEA transporter (Moore et al., 2005), or additional pathways (Piomelli et al., 2000; Di Marzo et al., 2004).”
BackgroundFatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo
Capasso, R., Matias, I., Lutz, B., Borrelli, F., Capasso, F., Marsicano, G., Mascolo, N., Petrosino, S., Monory, K., Valenti, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.018 · Cited by 144
“The endogenous cannabinoid system includes cannabinoid (CB1 and CB2) receptors, their endogenous ligands (the endocannabinoids), and the enzymes for the synthesis and inactivation of these ligands.(1,2) The endocannabinoids anandamide and 2-arachidonylglycerol (2-AG) may reduce gastrointestinal motility through activa…”
BackgroundSelf-citationSarnataro, D., Pisanti, S., Santoro, A., Gazzerro, P., Malfitano, A. M., Laezza, C., & Bifulco, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025601 · Cited by 143
“Moreover, as endocannabinoids through CB1R-dependent mechanism have been shown to have a role in cancer (De Petrocellis et al., 1998; Di Marzo et al., 2004; Grimaldi et al., 2006) and lipid rafts play a pivotal role in breast tumor cell invasion (Bourguignon et al., 2004), we decided first to check…”
BackgroundSelf-citationVan Laere, K., Goffin, K., Casteels, C., Dupont, P., Mortelmans, L., de Hoon, J., & Bormans, G. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.053 · Cited by 142
“The endogenous cannabinoid system (ECS) is thought to modulate multiple physiological processes in the human body (Di Marzo et al., 2004) and plays an important role in motor, reward and memory processes (Iversen, 2003).”
BackgroundDobrosi, N., Tóth, B. I., Nagy, G., Dózsa, A., Géczy, T., Nagy, L., Zouboulis, C. C., Paus, R., Kovács, L., & Bíró, T. (2008) · The FASEB Journal · doi:10.1096/fj.07-104877 · Cited by 142
New Drugs for Type 2 Diabetes Mellitus: What is their Place in Therapy?
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 141
“[161] The study examined the effects of rimonabant on metaendocannabinoid system has neuromodulatory funcbolic risk factors in high-risk patients who were tions on metabolic processes including food intake overweight or obese and also had untreated dysand energy homeostasis.[161] Endocannabinoids and lipidaemia.”
Therapeutic potential of cannabinoid medicines
Robson, P. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1529 · Cited by 141
Endocannabinoid Transport Revisited
Nicolussi, S., & Gertsch, J. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2014.12.011 · Cited by 141
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139
“The CB2 receptor couples through Gi/o proteins to inhibit adenylate cyclase and stimulate MAP kinase activities (Di Marzo et al., 2004).”
BackgroundThe Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 126
“Endocannabinoids themselves function as neuromodulators that are released by post-synaptic neurons, and bind to the presynaptic CB1Rs to moderate the release of neurotransmitters, such as gamma-aminobutyric-acid (GABA), glutamate, and dopamine (DA) (10, 12, 13).”
BackgroundMarzo, V. D. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.01.010 · Cited by 140
Self-citationThe endocannabinoid system of the skin. A potential approach for the treatment of skin disorders
del Río, C., Millán, E., García, V., Appendino, G., DeMesa, J., & Muñóz, E. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.08.022 · Cited by 138
Siegmund, S. V., Qian, T., de Minicis, S., Harvey‐White, J., Kunos, G., Vinod, K. Y., Hungund, B., & Schwabe, R. F. (2007) · The FASEB Journal · doi:10.1096/fj.06-7717com · Cited by 122
Tchantchou, F., & Zhang, Y. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2012.2647 · Cited by 123
Brioschi, F. A., Cesare, F. D., Gioeni, D., Rabbogliatti, V., Ferrari, F., D’Urso, E. S., Amari, M., & Ravasio, G. (2020) · Animals · doi:10.3390/ani10091505 · Cited by 134
“The endocannabinoid receptor system, composed of two cannabinoid receptors (CB1 and CB2) and their ligands, plays a role in pain modulation and inflammation attenuation [14].”
BackgroundCannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
Marzo, V. D., Piscitelli, F., & Mechoulam, R. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_4 · Cited by 132
“Endocannabinoids are then released from the cell immediately after their biosynthesis in ordertoactivatetheirtargetsandthenrapidlyremovedfromtheextracellularspaceby rapid and selective uptake into the cell and intracellular enzymatic hydrolysis ( Di Marzo et al. 2004 ).”
BackgroundSelf-citationCannabis and the developing brain: Insights from behavior
Trezza, V., Cuomo, V., & Vanderschuren, L. J. M. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.058 · Cited by 131
“…around cannabis has aided the understanding of its effects on the brain, and a number of reports have claimed cannabis derivates as novel, promising therapeutic tools for a variety of pathological conditions (Di Marzo et al., 2004; Lambert and Fowler, 2005; Mackie, 2006a; Pacher et al., 2006).”
Rise and fall of anti-obesity drugs
Li, M.-F. (2011) · World Journal of Diabetes · doi:10.4239/wjd.v2.i2.19 · Cited by 117
Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids
Hanuš, L. O. (2009) · Medicinal Research Reviews · doi:10.1002/med.20135 · Cited by 109
The endocannabinoid system and gut–brain signalling
Storr, M., & Sharkey, K. A. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.08.008 · Cited by 131
Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant
Gonçalves, E. C. D., Baldasso, G. M., Bicca, M. A., Paes, R. S., Capasso, R., & Dutra, R. C. (2020) · Molecules · doi:10.3390/molecules25071567 · Cited by 129
“, which is widely known as “hemp” and not psychoactive, as well as Cannabis sativa, which induces psychoactive effects [1].”
BackgroundMarsicano, G., & Kuner, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_10 · Cited by 126
Cannabinomics: Application of Metabolomics in Cannabis (Cannabis sativa L.) Research and Development
Aliferis, K. A., & Bernard-Perron, D. (2020) · Frontiers in Plant Science · doi:10.3389/fpls.2020.00554 · Cited by 126
Li, M., & Cheung, B. M. Y. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03453.x · Cited by 100
CB2 receptors as new therapeutic targets for liver diseases
Lotersztajn, S., Teixeira-Clerc, F., Julien, B., Deveaux, V., Ichigotani, Y., Manin, S., Nhieu, J. T. V., Karsak, M., Zimmer, A., & Mallat, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707511 · Cited by 123
“Among the growing family of endocannabinoids identified (for reviews, see Piomelli et al., 2000; Di Marzo et al., 2004), 2-arachidonoylglycerol (2-AG) has been proposed to serve as the endogenous CB2 ligand, although it is also a full agonist for CB1 receptors.”
BackgroundTrends in registered medical marijuana participation across 13 US states and District of Columbia
Fairman, B. J. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.015 · Cited by 122
Endocannabinoid System: Chemical Characteristics and Biological Activity
Rezende, B., Alencar, A. K. N., de Bem, G. F., Fontes-Dantas, F. L., & Montes, G. C. (2023) · Pharmaceuticals · doi:10.3390/ph16020148 · Cited by 121
Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse
da Cruz, J. F. O., Robin, L. M., Drago, F., Marsicano, G., & Metna‐Laurent, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.002 · Cited by 121
Endocannabinoid overactivity and intestinal inflammation
Di Marzo, V, & Izzo, A. A. (2006) · Gut · doi:10.1136/gut.2005.090472 · Cited by 107
Self-citationTabrizi, M. A., Baraldi, P. G., Borea, P. A., & Varani, K. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00411 · Cited by 119
Justinova, Z. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0951-05.2005 · Cited by 104
“However, it is believed that FAAH inhibitors promote the gradual accumulation of anandamide and augment CB1 signaling only in select brain areas in which FAAH-positive cell bodies are juxtaposed to axon terminals that contain CB1 receptors (Piomelli, 2003; Di Marzo et al., 2004).”
BackgroundSolinas, M., Tanda, G., Justinova, Z., Wertheim, C. E., Yasar, S., Piomelli, D., Vadivel, S. K., Makriyannis, A., & Goldberg, S. R. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114124 · Cited by 104
“Among the endogenous ligands for cannabinoid CB1 receptors, anandamide is the best-characterized (Freund et al., 2003; Piomelli, 2003; Di Marzo et al., 2004).”
BackgroundInfluentialInhibition of human hair follicle growth by endo‐and exocannabinoids
Telek, A., Bíró, T., Bodó, E., Tóth, B. I., Borbíró, I., Kunos, G., & Paus, R. (2007) · The FASEB Journal · doi:10.1096/fj.06-7689com · Cited by 113
Maccarrone, M., Battista, N., & Centonze, D. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.006 · Cited by 118
Griebel, G., Pichat, P., Beeské, S., Leroy, T., Redon, N., Jacquet, A., Françon, D., Bert, L., Even, L., Lopez-Grancha, M., et al. (2015) · Scientific Reports · doi:10.1038/srep07642 · Cited by 113
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use
Blebea, N. M., Pricopie, A. I., Vlad, R.-A., & Hancu, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084204 · Cited by 117
“Despite sharing 68% similarity in transmembrane domains and 44% overall, the receptors exhibit nuanced pharmacological profiles and expression patterns, allowing for diverse experimental studies, especially in murine models [10,11].”
BackgroundCzifra, G., Varga, A., Nyeste, K., Marincsák, R., Tóth, B. I., Kovács, I., Kovács, L., & Bíró, T. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0482-3 · Cited by 117
“signaling mechanisms very often interact, hence resulting in a complex, bi-directional regulatory relationship (Caterina and Julius 2001; De Petrocellis et al. 2004; Di Marzo et al. 2004; Paus et al. 2006).”
BackgroundKöfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 116
Lever, I. J., & Rice, A. S. C. (2007) · Springer eBooks · doi:10.1007/978-3-540-33823-9_10 · Cited by 115
The obesity epidemic and its cardiovascular consequences
Behn, A., & Ur, E. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231406.84554.96 · Cited by 115
Vemuri, K. V., Janero, D. R., & Makriyannis, A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.012 · Cited by 114
“3) have been studied clinically for alleviation of emesis; motor-related symptoms in patients with multiple sclerosis, Tourette's syndrome, or Parkinson's disease; intraocular pressure in glaucoma patients; neuropathic pain; or posttrauma brain damage [40].”
BackgroundInfluentialBátkai, S., Rajesh, M., Mukhopadhyay, P., Haskó, G., Liaudet, L., Cravatt, B. F., Csiszár, A., Ungvári, Z., & Pacher, P. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00373.2007 · Cited by 109
“Therefore, it is not surprising that there is considerable interest in the development of novel potent FAAH inhibitors for various inflammatory disorders and other therapeutic indications (10, 20, 32, 47).”
BackgroundSnider, N. T., Kornilov, A. M., Kent, U. M., & Hollenberg, P. F. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119321 · Cited by 114
“…system, which consists of cannabinoid receptors, endocannabinoids, and their associated signaling pathways, is known to play an important role in a number of physiological and pathophysiological processes, including drug addiction, obesity, inflammation, and cancer (Di Marzo et al., 2004).”
BackgroundLipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels
PETROCELLIS, L. D., & Marzo, V. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.05.021 · Cited by 114
Self-citationOxytocinSynthesis, Secretion, and Reproductive Functions
BURBACH, J., YOUNG, L., & RUSSELL, J. (2006) · Knobil and Neill's Physiology of Reproduction · doi:10.1016/b978-012515400-0/50063-4 · Cited by 113
Endocannabinoid system involvement in brain reward processes related to drug abuse
Solinas, M., Yaşar, S., & Goldberg, S. R. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.005 · Cited by 113
The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6
Snider, N. T., Sikora, M. J., Sridar, C., Feuerstein, T. J., Rae, J. M., & Hollenberg, P. F. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141796 · Cited by 106
“The various components of this system represent novel and important pharmacological targets in the treatment of many disorders, including neurodegeneration, chronic pain, inflammation, cancer, and others (Di Marzo et al., 2004).”
BackgroundIncreased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon
Izzo, A. A., Aviello, G., Petrosino, S., Orlando, P., Marsicano, G., Lutz, B., Borrelli, F., Capasso, R., Nigam, S., Capasso, F., et al. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0248-4 · Cited by 112
“Cannabinoids have been licensed for clinical use as palliative treatment of chemotherapy, but increasing evidence shows antitumor actions of cannabinoid agonists on several tumor cells in vitro and in animal models [4, 5].”
BackgroundInfluentialSelf-citationCompagnucci, C., Di Siena, S., Bustamante, M. B., Di Giacomo, D., Di Tommaso, M., Maccarrone, M., Grimaldi, P., & Sette, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054271 · Cited by 92
“We set out to investigate the possible involvement of AEA, an endogenous ligand that binds with similar affinity to CB1 and CB2 [9,15], in NSC differentiation.”
BackgroundInfluentialFan, N., Yang, H., Zhang, J., & Chen, C. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06489.x · Cited by 110
Korf, H. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.05.011 · Cited by 109
Solinas, M., Panlilio, L. V., Tanda, G., Makriyannis, A., Matthews, S. A., & Goldberg, S. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300754 · Cited by 109
CB1 receptor antagonism: biological basis for metabolic effects
Marzo, V. D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.001 · Cited by 110
Self-citationMarco, E. M., Echeverry‐Alzate, V., López‐Moreno, J. A., Giné, E., Peñasco, S., & Viveros, M. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000068 · Cited by 110
“More recently, an additional degradative pathway, for both AEA and 2-AG, that involves cyclooxygenase-2 (COX-2) has been proposed (Piomelli, 2003; Di Marzo et al., 2004; Battista et al., 2012).”
BackgroundStatement on safety of cannabidiol as a novel food: data gaps and uncertainties
EFSA Panel on Nutrition, N. F. A. F. A. (., Turck, D., Bohn, T., Castenmiller, J. J. M., Henauw, S. D., Hirsch‐Ernst, K. I., Maciuk, A., Mangelsdorf, I., McArdle, H. J., Naska, A., et al. (2022) · EFSA Journal · doi:10.2903/j.efsa.2022.7322 · Cited by 107
Toxicology of Marijuana, Synthetic Cannabinoids, and Cannabidiol in Dogs and Cats
Brutlag, A. G., & Hommerding, H. A. (2018) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2018.07.008 · Cited by 106
“Since the 1980s, synthetic THC–based medications dronabinol (Marinol) and analogue nabilone (Cesamet) have been used in treatment of inappetence and nausea in chemotherapy patients and patients with AIDS.3,7 Cannabis— including extracts of THC and CBD—are once again at the forefront of debate with respect to potential…”
BackgroundInfluentialAlba, R. G., Barragán‐Iglesias, P., González‐Hernández, A., Valdez-Moráles, E. E., Granados‐Soto, V., Condés‐Lara, M., Rodríguez, M. G., & Marichal‐Cancino, B. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01496 · Cited by 106
Amici, M. D., Dallanoce, C., Holzgrabe, U., Tränkle, C., & Mohr, K. (2009) · Medicinal Research Reviews · doi:10.1002/med.20166 · Cited by 106
“It has been shown that the endocannabinoid signaling system is affected in an array of pathologies such as neurological, psychiatric, cardiovascular, gastrointestinal, reproductive, and eating disorders.(148) As a consequence, several novel compounds targeting the endocannabinoid system, and mainly resulting from in s…”
BackgroundMedical Marijuana Use in Oncology: A Review
Wilkie, G., Sakr, B., & Rizack, T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0155 · Cited by 94
Eating disorders: the current status of molecular genetic research
Scherag, S., Hebebrand, J., & Hinney, A. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0085-9 · Cited by 88
“One of the endogenous systems that, due to its therapeutic potential in the treatment of obesity [112], recently reached scientific interest for ED is the endocannabinoid system.”
BackgroundRimonabant: The first therapeutically relevant cannabinoid antagonist
Carai, M. A. M., Colombo, G., & Gessa, G. L. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.04.017 · Cited by 105
Katz, P. S., Sulzer, J. K., Impastato, R. A., Teng, S. X., Rogers, E. K., & Molina, P. E. (2015) · Journal of Neurotrauma · doi:10.1089/neu.2014.3508 · Cited by 94
“Two principal ECs have been identified, 2arachidonoyl glycerol (2-AG) and N-arachidonoyl-ethanolamine (AEA), of which 2-AG is the most bioactive and abundant EC in the brain.(18,23) In contrast to preformed neurotransmitters, which are”
Fatty Acid Amide Hydrolase Determines Anandamide-induced Cell Death in the Liver
Siegmund, S. V., Seki, E., Osawa, Y., Uchinami, H., Cravatt, B. F., & Schwabe, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509706200 · Cited by 94
Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake
Chicca, A., Nicolussi, S., Bartholomäus, R., Blunder, M., Aparisi Rey, A., Petrucci, V., Reynoso-Moreno, I. D. C., Viveros-Paredes, J. M., Dalghi Gens, M., Lutz, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704065114 · Cited by 96
“The indirect modulation of EC levels may lead to fewer side effects than the direct activation of CB1 receptors in terms of neurotransmission, metabolism, and immunomodulation (7).”
BackgroundAllosterism and cannabinoid CB1 receptors: the shape of things to come
ROSS, R. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.006 · Cited by 102
The endocannabinoid system mediates aerobic exercise-induced antinociception in rats
Galdino, G., Romero, T. R. L., Silva, J. F. P., de Aguiar, D. C., de Paula, A. M., Cruz, J. S., Parrella, C., Piscitelli, F., Duarte, I. D. G., Marzo, V. D., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.022 · Cited by 103
“The endocannabinoid arachidonoylethanolamide (anandamide, or AEA) is hydrolyzed by the enzyme fatty acid amide hydrolase (FAAH), whereas the other endogenous cannabinoid receptor ligand, 2-arachidonoylglycerol (2-AG), is degraded by the enzyme monoacylglycerol lipase (MGL) (Di Marzo et al., 2004).”
Self-citationZheng, D., Bode, A. M., Zhao, Q. J., Cho, Y., Zhu, F., Ma, W.-Y., & Dong, Z. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6594 · Cited by 102
“Both CB1 and CB2 receptors are coupled to Gi/o proteins, through which they stimulate the activity of the MAP kinases (33).”
BackgroundCannabis and neurodevelopment: implications for psychiatric disorders
Sundram, S. (2006) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.762 · Cited by 89
“Through Gi/o the CB1 receptor inhibits adenylate cyclase, however, in addition, its other signalling effects include stimulating mitogen activated protein kinases, closing Ca2þ channels and opening Kþ channels (Di Marzo et al., 2004).”
Background“Not for Human Consumption”: A Review of Emerging Designer Drugs
Musselman, M. E., & Hampton, J. P. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1424 · Cited by 101
“The CB2 receptors are predominately in the periphery, such as blood cells, immune tissues, and spleen, and they mediate the immunomodulatory effects of cannabinoids.(19) The CB1 and CB2 receptors are G-protein–coupled receptors that respond to the endogenous ligands anandamide and noladin ether.”
BackgroundDrug discovery and development with plant-derived compounds
Potterat, O., & Hamburger, M. O. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8117-2_2 · Cited by 101
Panagis, G., Mackey, B., & Vlachou, S. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00092 · Cited by 85
“For the past couple of decades, with the contribution of various research groups, it has been discovered that the endocannabinoid system is composed of cannabinoid 1 and 2 receptors (CB1, CB2, respectively, and possibly others), endogenous ligands for these receptors and enzymes responsible for the synthesis, reuptake…”
BackgroundValenti, M., Cottone, E., Martinez, R., de Pedro, N., Rubio, M., Viveros, M., Franzoni, M. F., Delgado, M. J., & Marzo, V. D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03406.x · Cited by 95
“…of substrate (1, 4, 10, 50 and 100 lM) at pH 9.0, with 4 lM substrate in buffers at different pH (De Petrocellis et al. 1999) or in the presence of two distinct inhibitors of mammalian fatty acid amide hydrolase (FAAH), OL-135 and arachidonoylserotonin (see Di Marzo et al. 2004 for a review).”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.